Gilead woos Cindy Perettie from Roche to lead Kite af­ter Christi Shaw de­parts

Gilead has found the next leader for Kite in Roche on­col­o­gy vet Cindy Perettie, putting her in charge of a cell ther­a­py unit that brought in $1.5 bil­lion in 2022.

Perettie joins Gilead as EVP of Kite al­most two months af­ter for­mer Kite CEO Christi Shaw stepped down. While Perettie spent the past few years in the di­ag­nos­tics world — first as CEO of Foun­da­tion Med­i­cine and lat­er head­ing Roche’s Mol­e­c­u­lar Lab So­lu­tions af­ter Roche bought Foun­da­tion — she al­so had a back­ground in on­col­o­gy drug de­vel­op­ment and com­mer­cial­iza­tion, be­gin­ning at Genen­tech and lat­er at Roche.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN